FDA Approves Tauklarify, a New Tau-Targeted PET Tracer for Alzheimer's Diagnostic Workup

People often think Alzheimer's disease is a single, uniform condition that can be diagnosed with a simple memory test. In reality, it is a complex biological process driven by two distinct proteins—amyloid plaques and tau tangles—that require highly specific tools to detect. For years, clinicians have relied on amyloid imaging and spinal fluid tests, but getting a complete picture of a patient's brain pathology has remained a challenge.[5]

On August 14, the FDA approved Tauklarify (florquinitau F 18 injection), a new radiodiagnostic agent for positron emission tomography (PET) imaging. Developed by Lantheus and Enigma Biomedical USA, the tracer is indicated for adults with cognitive impairment who are being evaluated for Alzheimer's disease. The approval adds a critical tool alongside amyloid imaging to help confirm diagnoses and guide treatment.[1][2]

Tauklarify, previously known in research as MK-6240, binds selectively to aggregated tau protein in the brain. When a patient undergoes a PET scan, the tracer lights up these tau neurofibrillary tangles, allowing radiologists to see exactly where and how much tau has accumulated. This direct visualization is crucial because tau tangles correlate closely with cognitive decline and disease severity.[1][4]

The approval was backed by two pivotal clinical studies involving over 500 individuals, ranging from cognitively unimpaired adults to those with mild Alzheimer's dementia. Across the trials, independent readers achieved a 68% to 88% positive agreement and a 93% to 99% negative agreement with the study's reference standard, demonstrating the tracer's reliability in a clinical setting.[1][3]

However, the FDA and the manufacturer caution that the tool is not foolproof. A negative scan does not entirely rule out early-stage tau pathology, and a positive scan does not independently confirm histopathologically confirmed disease. Furthermore, the agent's safety and effectiveness have not been established for other neurodegenerative diseases known as non-Alzheimer tauopathies.[1][2]

The addition of a tau-specific tracer complements existing amyloid PET scans and emerging blood-based biomarkers. As the pharmaceutical industry shifts toward precision medicine for Alzheimer's, having a complete molecular picture of a patient's brain will be essential for determining who will actually benefit from newly approved disease-modifying therapies.[1][5]

In clinical trials, Tauklarify was generally well-tolerated. The most commonly reported adverse reactions across more than 1,700 exposed individuals were mild, including headache, nausea, and injection site reactions, each occurring in less than one percent of subjects. Patients are advised to hydrate before and after administration to minimize radiation exposure.[1][2]

Following the approval, Lantheus intends to continue supporting Alzheimer's disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability. The rollout approach will remain aligned with the needs of diagnostic partners and informed by ongoing developments across the Alzheimer's disease treatment landscape.[1]